G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis
Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVDs), is a lipid-driven, inflammatory disease of the large arteries. Gold standard therapy with statins and the more recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have improved he...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00531/full |
id |
doaj-634a0b8d5f434e89ae249c6540f88d2f |
---|---|
record_format |
Article |
spelling |
doaj-634a0b8d5f434e89ae249c6540f88d2f2020-11-25T01:17:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-05-011010.3389/fphar.2019.00531451850G-Protein Coupled Receptor Targeting on Myeloid Cells in AtherosclerosisEmiel P. C. van der Vorst0Emiel P. C. van der Vorst1Emiel P. C. van der Vorst2Emiel P. C. van der Vorst3Linsey J. F. Peters4Madeleine Müller5Selin Gencer6Yi Yan7Christian Weber8Christian Weber9Christian Weber10Yvonne Döring11Yvonne Döring12Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyDepartment of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, NetherlandsInstitute for Molecular Cardiovascular Research/Interdisciplinary Center for Clinical Research, RWTH Aachen University, Aachen, GermanyMunich Heart Alliance, German Centre for Cardiovascular Research, Munich, GermanyInstitute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyInstitute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyInstitute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyInstitute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyInstitute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyMunich Heart Alliance, German Centre for Cardiovascular Research, Munich, GermanyDepartment of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, NetherlandsInstitute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, GermanyMunich Heart Alliance, German Centre for Cardiovascular Research, Munich, GermanyAtherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVDs), is a lipid-driven, inflammatory disease of the large arteries. Gold standard therapy with statins and the more recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have improved health conditions among CVD patients by lowering low density lipoprotein (LDL) cholesterol. Nevertheless, a substantial part of these patients is still suffering and it seems that ‘just’ lipid lowering is insufficient. The results of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) have now proven that inflammation is a key driver of atherosclerosis and that targeting inflammation improves CVD outcomes. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways have to be promoted. The inflammatory processes in atherosclerosis are facilitated by a network of immune cells and their subsequent responses. Cell networking is orchestrated by various (inflammatory) mediators which interact, bind and induce signaling. Over the last years, G-protein coupled receptors (GPCRs) emerged as important players in recognizing these mediators, because of their diverse functions in steady state but also and specifically during chronic inflammatory processes – such as atherosclerosis. In this review, we will therefore highlight a selection of these receptors or receptor sub-families mainly expressed on myeloid cells and their role in atherosclerosis. More specifically, we will focus on chemokine receptors, both classical and atypical, formyl-peptide receptors, the chemerin receptor 23 and the calcium-sensing receptor. When information is available, we will also describe the consequences of their targeting which may hold promising options for future treatment of CVD.https://www.frontiersin.org/article/10.3389/fphar.2019.00531/fullG-protein coupled receptorsmyeloid cellscardiovascular diseaseatherosclerosistherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Emiel P. C. van der Vorst Emiel P. C. van der Vorst Emiel P. C. van der Vorst Emiel P. C. van der Vorst Linsey J. F. Peters Madeleine Müller Selin Gencer Yi Yan Christian Weber Christian Weber Christian Weber Yvonne Döring Yvonne Döring |
spellingShingle |
Emiel P. C. van der Vorst Emiel P. C. van der Vorst Emiel P. C. van der Vorst Emiel P. C. van der Vorst Linsey J. F. Peters Madeleine Müller Selin Gencer Yi Yan Christian Weber Christian Weber Christian Weber Yvonne Döring Yvonne Döring G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis Frontiers in Pharmacology G-protein coupled receptors myeloid cells cardiovascular disease atherosclerosis therapy |
author_facet |
Emiel P. C. van der Vorst Emiel P. C. van der Vorst Emiel P. C. van der Vorst Emiel P. C. van der Vorst Linsey J. F. Peters Madeleine Müller Selin Gencer Yi Yan Christian Weber Christian Weber Christian Weber Yvonne Döring Yvonne Döring |
author_sort |
Emiel P. C. van der Vorst |
title |
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis |
title_short |
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis |
title_full |
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis |
title_fullStr |
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis |
title_full_unstemmed |
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis |
title_sort |
g-protein coupled receptor targeting on myeloid cells in atherosclerosis |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-05-01 |
description |
Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVDs), is a lipid-driven, inflammatory disease of the large arteries. Gold standard therapy with statins and the more recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have improved health conditions among CVD patients by lowering low density lipoprotein (LDL) cholesterol. Nevertheless, a substantial part of these patients is still suffering and it seems that ‘just’ lipid lowering is insufficient. The results of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) have now proven that inflammation is a key driver of atherosclerosis and that targeting inflammation improves CVD outcomes. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways have to be promoted. The inflammatory processes in atherosclerosis are facilitated by a network of immune cells and their subsequent responses. Cell networking is orchestrated by various (inflammatory) mediators which interact, bind and induce signaling. Over the last years, G-protein coupled receptors (GPCRs) emerged as important players in recognizing these mediators, because of their diverse functions in steady state but also and specifically during chronic inflammatory processes – such as atherosclerosis. In this review, we will therefore highlight a selection of these receptors or receptor sub-families mainly expressed on myeloid cells and their role in atherosclerosis. More specifically, we will focus on chemokine receptors, both classical and atypical, formyl-peptide receptors, the chemerin receptor 23 and the calcium-sensing receptor. When information is available, we will also describe the consequences of their targeting which may hold promising options for future treatment of CVD. |
topic |
G-protein coupled receptors myeloid cells cardiovascular disease atherosclerosis therapy |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.00531/full |
work_keys_str_mv |
AT emielpcvandervorst gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT emielpcvandervorst gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT emielpcvandervorst gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT emielpcvandervorst gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT linseyjfpeters gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT madeleinemuller gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT selingencer gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT yiyan gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT christianweber gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT christianweber gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT christianweber gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT yvonnedoring gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis AT yvonnedoring gproteincoupledreceptortargetingonmyeloidcellsinatherosclerosis |
_version_ |
1725145264395649024 |